Emeis stock rebounds above €9.89 after dipping to €9.80
The elderly care facilities manager bounces back mid-session after falling below a technical level that has been closely watched for several days. The stock, significantly lagging its medium-term benchmarks, ranks among the strongest gainers in the index.
A support level breached in-session then reclaimed after a prolonged slide
Based on session data, Emeis stock gains 2.11% to €10.15, while the SBF 120 advances 0.11%. This gain places it among the strongest rises in the index. The stock fell below its €9.89 support level in the morning, reaching a low of €9.80, before rebounding above it.
This level had already been broken during trading on October 9, then recovered, as shown by last Friday's rebound. The RSI at 24 reflects the magnitude of the recent decline: the price is still down 18.93% over one month. This rebound only recovers a small portion of this decline.
A price more than 26% below its 200-day moving average
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price remains well below its moving averages: the 20-day MA stands at €11.08, or 8.39% above the price, while the 200-day MA, at €13.79, is 26.40% above it. Over three months, the stock is down 27.29%. The most recent financial report, for the first half of 2026 published on July 29, showed a more favorable trajectory: the group raised its 2026 guidance, with the half-year performance exceeding initial expectations. In a market where the 10-year OAT stands at 4.86% according to the latest Banque de France reading (October 12), the €9.89 support level remains the key level to watch in the coming sessions.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3 011 millions d'euros
Quarterly revenue: 3 011 millions d'euros
EBITDA: 461 millions d'euros
EBITDA margin: 15,3 %
Net income: -40,4 millions d'euros
Free cash flow: -153 millions d'euros
3 862 millions d'euros
Guidance from the release
First-half performance allows for an upward revision of the 2026 guidance; the trend since the start of the year confirms the continued momentum observed in 2025 and even shows performance that exceeded the Group's initial expectations
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
